Genomics England has chosen Congenica to provide clinical decision support services for the NHS Genomic Medicine Service, which is seeking to make genetic testing routing in healthcare.
Efficiently translating genomic research into the clinic is one of the most important steps in the development of the field. The clinic is where we will see things come to fruition.
Genome Sequencing Found Feasible and Informative for Pediatric Cancer Treatment Findings Reported at ASHG 2018 Annual Meeting
Presenting author Scott Newman, PhD; Jinghui Zhang, PhD; and Kim Nichols, MD, along with an interdisciplinary team at St. Jude Children’s Research Hospital, studied 253 pediatric oncology patients with a variety of cancers.
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.
For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth.
Rady Children’s Hospital has launched a new, California State-funded initiative called Project Baby Bear to cover rWGS for critically ill newborns across the state.
Human genome sequencing on PromethION: characterization of structural variants and repetitive regions
At the VIB-UAntwerp Center for Molecular Neurology, we apply sequencing technologies to elucidate the genetic etiology of neurodegenerative brain diseases such as Alzheimer Disease and Frontotemporal Dementia. Structural variation and repetitive regions are insufficiently characterized using currently dominant short-read sequencing technologies. Long-read sequencing on the Oxford Nanopore PromethION has the potential for a comprehensive […]
Precision medicine is showing significant signs of success across tumour types.
With artificial intelligence, machines can now examine thousands of medical images for signs of disease. Will this technology replace doctors – or work side by side with them?
A type of enzyme called matrix metalloproteinase could be key to the development of “smart” cancer drugs, according to new research.
Americans are more likely to anticipate negative than positive effects from widespread use of gene-editing technology.